Alpine BioVentures names Venkatesan as managing partner

Seattle-based venture firm Alpine BioVentures has appointed Dr. Jay Venkatesan as a managing partner. Venkatesan is the former executive vice president and general manager of Oncothyreon Inc, which he joined after it was acquired by Alpine Biosciences. Also, he was a founder, portfolio manager and managing director of Ayer Capital Management.

PRESS RELEASE

SEATTLE–(BUSINESS WIRE)–Alpine BioVentures, a Seattle-based venture capital firm committed to investing in and building revolutionary healthcare companies, today announced that Jay Venkatesan, M.D., has joined as a managing partner. As a managing partner, Dr. Venkatesan will lead the creation of new companies, identify investment opportunities and collaborate with innovators to develop game-changing therapies that can meaningfully impact patients’ lives.

“Jay’s extensive investment and management experience and his track record of success in the healthcare and biotech industry will be invaluable to Alpine BioVentures as we work to build successful and meaningful healthcare companies that have the potential to significantly impact patients’ lives,” said Mitchell H. Gold, M.D., founder and managing partner of Alpine BioVentures. “I am thrilled to re-join forces with Jay to build on our previous success at Alpine Biosciences as we look to integrate novel and innovative science into our portfolio of new companies.”

Prior to joining Alpine BioVentures, Dr. Venkatesan was the executive vice president and general manager of Oncothyreon, Inc., which he joined after it was acquired by Alpine Biosciences, where he served as co-founder and CEO. Previously, Dr. Venkatesan was the founder, portfolio manager and managing director of Ayer Capital Management, a global healthcare long-short equity fund. Prior to that, he served as a director at Brookside Capital Partners, the hedge fund group affiliated with Bain Capital, where he co-managed healthcare investments and evaluated public and private investments in all healthcare subsectors. Earlier in his career, Dr. Venkatesan was involved in healthcare venture investing at Patricof & Co. Ventures (now Apax Partners) and consulting at McKinsey & Company.

In addition, Dr. Venkatesan currently serves on the Board of Directors of Lion Biotechnologies and AuraSense Therapeutics. He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.

About Alpine BioVentures
Alpine BioVentures is a venture capital firm committed to investing in and building revolutionary healthcare companies. It brings a unique perspective to identify game-changing scientific ideas and actively build collaborative working relationships with companies to bring new science to patients faster. The Alpine BioVentures team leverages decades of experience and strong relationships with leading research labs and corporate partners in the United States and around the world to grow a portfolio of companies with the potential to help people living with cancer, autoimmune conditions and orphan diseases. The company’s portfolio includes Alpine Immune Sciences and Alpine Biosciences, which was acquired by Oncothyreon in 2014.

For more information about Alpine BioVentures, visit the company’s website at www.alpinebioventures.com.